Biotest

Biotest, a Pharmaceutical Preparation Manufacturing company headquartered in Germany, reported total greenhouse gas emissions of approximately 130,372,600 kg CO2e in 2025. This includes Scope 1 emissions of approximately 17,480,600 kg CO2e, Scope 2 market-based emissions of approximately 26,000,500 kg CO2e, and Scope 3 emissions of approximately 86,891,500 kg CO2e. The Scope 3 emissions for 2025 encompassed categories such as purchased goods and services (60,054,400 kg CO2e), capital goods (6,485,300 kg CO2e), fuel and energy related activities (6,312,600 kg CO2e), waste generated in operations (5,892,300 kg CO2e), and upstream transportation and distribution (4,062,500 kg CO2e).

In 2024, Biotest's total emissions were approximately 134,539,400 kg CO2e, comprising Scope 1 emissions of approximately 17,035,400 kg CO2e, Scope 2 market-based emissions of approximately 25,289,000 kg CO2e, and Scope 3 emissions of approximately 92,215,000 kg CO2e.

For 2023, the company's total emissions were approximately 139,158,000 kg CO2e, with Scope 1 emissions at approximately 15,210,000 kg CO2e, Scope 2 market-based emissions at approximately 21,905,000 kg CO2e, and Scope 3 emissions totalling approximately 102,043,000 kg CO2e.

In 2022, Biotest reported Scope 1 emissions of approximately 18,185,600 kg CO2e and Scope 2 emissions of approximately 930,500 kg CO2e. The total Scope 1 and 2 emissions for 2022 were approximately 19,116,100 kg CO2e.

Looking further back, in 2021, Biotest's reported total emissions were approximately 2,054,400 kg CO2e, with Scope 1 emissions of approximately 1,136,500 kg CO2e and Scope 2 emissions of approximately 711,000 kg CO2e.

The company's emissions data for 2019, 2020, 2021, 2022, 2023, 2024, and 2025 are inherited from its own reporting as Biotest Aktiengesellschaft. Science Based Targets Initiative (SBTi) targets are cascaded from its ultimate parent, Grifols, S.A., through a corporate family relationship. Biotest has not disclosed any specific emissions reduction targets.